Bone loss and fractures are emerging as important lupus-related conditions paralleling increased SLE incidence and survival. Bone loss in SLE is likely a multifactorial process involving both traditional and SLE-related risk factors for osteoporosis. Improved recognition of these risk factors is essential for early identification and prompt initiation of preventive measures to minimize further bone loss and fracture risk. Currently available knowledge on agents used in the prevention and treatment of osteoporosis in SLE is largely derived from studies performed in the non-SLE population. Therefore, awareness of specific caveats in the use of bone protective agents germane to SLE is important to optimize bone health and minimize therapeutic toxicity in the SLE patient.
ASJC Scopus subject areas